INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--EX US, UK and UAE Medical Media Only. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a 24-week open label arm ...

Boehringer Ingelheim announced results from its four Phase 3 trials of linagliptin for the treatment of type 2 diabetes. The aim of the four, 24-week, international, randomized, double-blind, ...

Linagliptin is the only diabetes treatment to be approved once daily, one dosage strength for all adult patients without any need for dose adjustments Ingelheim, Germany 25.08.2011- Boehringer ...

Amit Bansal, Managing Director, Theon Pharmaceuticals Ltd says this fixed-dose combination tablet of linagliptin, dapagliflozin, and metformin hydrochloride is a suitable option for the following ...

Review the side-effects of Linagliptin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Sulfonylureas are often added to metformin to improve glycemic control, but at the known risk of increasing hypoglycemia and weight gain. In a report published in the Lancet, more than 1,500 patients ...

Senior patient in hospital explaining pain to doctor or nurse Linagliptin is safe for patients with type 2 diabetes and cardiorenal disease. SAN FRANCISCO — Linagliptin is safe for patients with type ...

Boehringer Ingelheim (BI) has released a fistful of data from Phase III clinical trials showing that the DPP-4 inhibitor linagliptin, the most advanced compound in the company’s diabetes portfolio, ...

San Diego, CA - Linagliptin (Tradjenta, Boehringer Ingelheim) shows similar efficacy to glimepiride (Amaryl, Sanofi-Aventis) for the treatment of patients with type 2 diabetes, in terms of controlling ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Whether already on metformin or ...

Linagliptin is the only DPP-4 inhibitor to be approved at one dosage strength for adults with type 2 diabetes in Europe, without any need for dose adjustments RIDGEFIELD, Conn., and INDIANAPOLIS, Aug.